Experimental

Experimental Pharmacology & Oncology Berlin-Buch (EPO) is a leading contract research organization (CRO) specializing in preclinical oncology services. The company provides a comprehensive range of in vitro and in vivo drug development services, leveraging an extensive library of patient-derived xenograft (PDX) models across various cancer types. EPO supports pharmaceutical and biotech partners in evaluating the efficacy, pharmacokinetics, and safety of novel therapeutic candidates, including small molecules, biologics, and advanced cell therapies. Their expertise extends to specialized areas such as immune-oncology, radio-oncology, and the development of personalized medicine strategies.